Thalidomide: Current uses

BioDrugs

Volumn 11, Issue 6, 1999, Pages 409-416

  Powell, Richard J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INTEGRIN; METRONIDAZOLE; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BEHCET DISEASE; CONTRACEPTION; DISCOID LUPUS ERYTHEMATOSUS; DRUG TOLERANCE; DRUG USE; ENTERITIS; ERYTHEMA MULTIFORME; GRAFT VERSUS HOST REACTION; HISTIOCYTOSIS; HUMAN; LEPROSY; LICHEN PLANUS; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MELKERSSON ROSENTHAL SYNDROME; NEUROPATHY; PHOTODERMATOSIS; PRACTICE GUIDELINE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN DISEASE; TERATOGENICITY; TOXIC EPIDERMAL NECROLYSIS; WEBER CHRISTIAN PANNICULITIS;

EID: 0033051201     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911060-00005     Document Type: Review

References (79)

1. 1. Burley DM, Dennison TC, Harrison W. Clinical experience with a new sedative drug. Practitioner 1959; 183: 57-61
2. 2. Dally A. Thalidomide: was the tragedy preventable? Lancet 1998; 351: 1197-9
3. 3. Winter W, Frankus E. Thalidomide enantiomers [letter]. Lancet 1992; 339: 365
4. 4. Sheskin I. Further observations with thalidomide in lepra reactions. Lepr Rev 1965; 36: 183-7
5. 5. Sampaio EP, Moreira AL, Sarno EN, et al. Prolonged treatment with recombinant interferon g induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175: 1729-37
6. 6. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993; 67: 1-17
7. 7. McHugh SM, Rowland TL. Thalidomide and derivatives: immunological investigations of tumour necrosis factor alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 1997; 110: 151-4
8. 8. Gardner-Medwin JMM, Smith NJ, Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiologicul studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53: 828-32
9. 9. Ochonisky S, Verroust J, Bastuji-Garin S et al. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994; 66-9
10. 10. Iyer CGS, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971; 45: 719-32
11. 11. Jadhav VH, Pakti AH, Mehta JM. Thalidomide in type-2 lepra reaction: a clinical experience. Indian J Lepr 1990; 62: 316-20
12. 12. Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985; 22: 165-242
13. 13. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumour necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1 (4): 384-97
14. 14. Sagher F. Thalidomide neuropathy. Lepr Rev 1969; 40(2): 126-30
15. 15. Powell RJ, Gardner Medwin JMM. Guideline for the clinical use and dispensing of ihalidomide. Postgrad Med J 1994; 70: 901-4
16. 16. Chajek T, Fainaru M. Behcet's disease. Report of 41 cases and it review of the literature. Medicine (Baltimore) 1975; 54: 179-96
17. 17. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990; 335: 1078-80
18. 18. Lehner T, Barnes CG. Criteria for diagnosis and classification of Behcet's syndrome. In: Lehner T, Barnes CG editors. Behcet's Syndrome: clinical and immunological features. London: Academic Press, 1979: 1-9
19. 19. Honma T, Morioka DDM. Electron microscopic study on the pathogenesis of recurrent aphthous ulceration as compared to Behcet's syndrome. Oral Surg 1976; 41 (3): 366-77
20. 20. Mascaro JM, Lecha M, Torra H. Thalidomide in the treatment of recurrent necrotic and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979; 115: 636-7
21. 21. Saylan T, Saltik I. Thalidomide in the treatment of Behcet's syndrome [letter]. Arch Dcrmatol 1982; 118: 536
22. 22. Hamuryudan V, Mat C, Saip S, et al. Randomised and placebo controlled trial of two different doses of thalidomide in Behcet's syndrome [abstract no. 210]. Am Coll Rheumatol 1997 Nov; 9 (40 Suppl.): 565
23. 23. Revuz J, Guillaume J-C, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent apthous stomatitis. Arch Dermatol 1997: 126; 923-7
24. 24. Greenspan D, Greenspan JS. HIV-related oral disease. Lancet 1996; 348: 729-33
25. 25. Youle M, Clabour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody [letter]. BMJ 1989; 298: 432
26. 26. Ryan J, Coleman J, Pedersen J, et al. Thalidomide to treat esophageal ulcers in AIDS. N Engl J Med 1992; 327: 208-9
27. 27. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with Human Immunodeficiency Virus: Successful treatment with thalidomide. J Am Acad Dermatol 1990; 23: 523-5
28. 28. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with Human Immunodeficiency Virus infection. N Engl J Med 1997; 336: 1487-92
29. 29. Hillman RJ, Goldmeier D, Taylor-Robinson D. Scrotal ulceration in HIV-positive patients. Genitourin Med 1990; 66: 93-4
30. 30. Strazzi S, Lebbe C, Geoggray C, et al. Aphthous ulceration in HIV-infected patients: treatment with thalidomide. Gcnit-ourin Med 1992; 68: 424-5
31. 31. Verberkmoes A, Boer K, Wertheim PME, et al. Thalidomide for genital ulcer in HIV-positive woman [letter]. Lancet 1996; 347: 974
32. 32. Alexander LN, Wilcox CM, United SOA. A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers. AIDS Res Hum Reiroviruses 1997; 13: 301-4
33. 33. Fu CS, Conteas CN. Successful treatment of HIV prortitis using thalidomide [abstract]. Am J Gastroenterol 1997; 92: 1675
34. 34. Reves-Teran G, Sierra-Madero JG, Martainez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-7
35. 35. Williams I, Weller IVD, Malin A, et al. Thalidomide hypersensitivity in AIDS. Lancet 1991; 337: 436-7
36. 36. Vogelsang GB, Hess AD, Gordon G, et al. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986; 41: 644-7
37. 37. Lim SH, McWhannell A, Vora AJ, et al. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation [letter]. Lancet 1988; 1: 117
38. 38. McCarthy DM, Kanfer J, Taylor E, et al. Thalidomide for graft-versus-host disease [letter]. Lancet 1988; 11: 1135
39. 39. McCarthy DM, Kanfer J, Barrett AJ. Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation. Biomed Pharmacother 1989; 43: 693-7
40. 40. Heney D, Bailey CC, Lewis IJ. Thalidomide in the treatment of graft-versus-host diease. Biomed Pharmacother 1990; 44: 199-204
41. 41. Heney D, Norfolk DR, Wheeldon J, et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-7
42. 42. Vogelsang GB, Evan MD, Farmer HR, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055-8
43. 43. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604-9
44. 44. Waters MFR, Laing ABG, Amhikapathy A, et al. Treatment of ulcerative colitis with thalidomide. BMJ 1979; 123: 792
45. 45. Larsson H. Case report treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217). J Int Med 1990; 228: 405-7
46. 46. Wettstein AR, Mcagher AP. Thalidomide in Crohn's Disease. Lancet 1997; 350: 1445-6
47. 47. Gutierrez-Rodriguez O. Thalidomide: a promising new treatment for rheumatoid arthritis. Arth Rheum 1984; 27: 1118-21
48. 48. Scoville CD. Results of the extension phase of the open trial of thalidomide in the treatment of rheumatoid arthritis [abstract]. Arth Rheum 1996; 39 Suppl.: S281
49. 49. Lee S, Klausner J, Oliver S, et al. Treatment of rheumatoid arthritis with thalidomide [abstract]. Arth Rheum 1996; 39 Suppl.: S282
50. 50. Huizinga TWJ, Dijkmans BAC, van der Velde EA, et al. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996; 55: 833-6
51. 51. McCormick PA, Scott F, Epstein O, et al. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled study. J Hepatol 1994; 21: 496-9
52. 52. Safa G, Joly P, Boullie MC, et al. Syndrome de Melkerson-Rosenthal Traile par le Thalidomide, Deux observations. Ann Dermatol Venereol 1995; 122: 609-11
53. 53. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus erythemateux chronique. Ann Dermatol Venereol 1980; 107: 515-23
54. 54. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983; 108: 461-6
55. 55. Stevens RI, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheum 1997: 36: 353-9
56. 56. Sheskin J. Zur Therapie der Prurigo Nodularis Hyde mit Thalidomid. Hautarzt 1975; 26: 215-7
57. 57. Clemmensen OJ, Zander Olsen P, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984; 120: 338-41
58. 58. Wulff CH, Hoyer H, Asboe-Hansen G, et al. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985; 112: 475-80
59. 59. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326-8
60. 60. Dominguez L, Hojyo MT. Actinic prurigo, a variety of polymorphous light eruption. Int J Dermatol 1982; 21: 260-1
61. 61. Carmichael AJ, Knight A. Thalidomide: a restricted role [letter]. Lancet 1992; 339: 1362
62. 62. Bahmer FA, Zaun H, Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Ada Derm Venereol Suppl (Stockh) 1982; 62: 449-50
63. 63. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent crythema multiforme. Br J Dermatol 1992; 126: 92-3
64. 64. Laugier P, Hunziker N, Harms M, et al. Case demonstrations at the Geneva University Dermatology Clinic. Dermatologica 1982; 165: 271-8
65. 65. DeCock KM. Treatment of ulcerative colitis [letter]. BMJ 1979; 1: 1356
66. 66. Eravelly J, Waters MFR. Thalidomide in Weber-Christian Disease [letter]. Lancet 1977; 1: 251
67. 67. Dereure O, Basset-Seguin N, Guilho J-J. Erosive lichen planus: dramatic response to thalidomide. Arch Dermatol 1996; 132: 1392-3
68. 68. Menendez-Ramos F, Razquin-Murillo J, Jimenez-Sanchez F, et al. Sucessful treatment of a case of erosive plantar lichen planus with thalidomide. Australas J Dermatol 1997; 38 Suppl. 2: 216-7
69. 69. Carlesimo M, Giustini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32: 866-9
70. 70. Giustini S, Carlesimo M, Innocenzi D, et al. Abstract. International Meeting Skin Therapy Update 1994, 94: 213
71. 71. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adults Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol 1993; 129: 1261-4
72. 72. Misery L, Larbre B, Lyonnet S, et al. Remission of Langerhans Histiocytosis with thalidomide treatment [letter]. Clin Exp Dermatol 1993; 18: 487
73. 73. Menuir I, Marck Y, Ribeyre C et al. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment [letter]. Br J Dermatol 1995; 132: 168
74. 74. Moulin G, Bonnet F, Barrut R, et al. Treatment of Jessner-Kanof disease with thalidomide. Ann Dermatol Venereol 1983; 110 (8): 611-4
75. 75. Guillaume JC, Moulin G, Dieng MT, et al. Crossover study of thalidomide vs placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995: 131 (9): 1032-5
76. 76. Wolkenstein P, Latarjet J, Roujeau J-C, et al Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998: 352: 1586-9
77. 77. Rifkin IR, McHugh SM, Bradley JR, et al. Thalidomide as treatment lor refractory systemic vasculitis: possible mechanism of action [letter]. Nephrol Dial Transplant 1994; 9: 1684
78. 78. Silva SRB, Viana PCF, Lugon NV, et al. Thalidomide for the treatment of uremic pruritis: a crossover randomized double trial. Nephron: 67: 270-3
79. 79. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996: 2 (4); 506-15